Condition: Relapsed or Refractory Multiple Myeloma · Sponsor: AbbVie
Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain, fractures, infections, hypercalcemia, and renal failure. This study aims to evaluate the safety and change in disease activity of etentamig in combination with pomalidomide compared with standard available therapies in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment, including lenalidomide. Etentamig is an investigational drug being developed for the treatment of relapsed or refractory multiple myeloma. This is a randomized, open-label study. The study will include a safety run-in portion and a randomized portion. The safety run-in participants will receive etentamig in combination with pomalidomide. The randomized portion of the study participants will receive either etentamig with pomalidomide or Standard Available Therapies (SATs). Approximately 520 participants will be enrolled in the study at approximately 200 sites worldwide. Prior to initiation of the randomized portion of the study, the safety run-in will be conducted in which participants will receive etentamig injections plus oral pomalidomide. Following review of the safety run-in data and per protocol-defined criteria, the study will advance to the randomized portion where participants will be randomized to receive either etentamig …
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| University of Arizona Cancer Center /ID# 285339 | Tucson, Arizona, United States | — |
| Toi Clinical Research - Whittier /ID# 284462 | Cerritos, California, United States | — |
| University of California Los Angeles /ID# 282444 | Los Angeles, California, United States | — |
| University Of Colorado - Anschutz Medical Campus /ID# 283478 | Aurora, Colorado, United States | — |
| MedStar Georgetown University Hospital /ID# 283734 | Washington D.C., District of Columbia, United States | — |
| Cleveland Clinic Florida /ID# 283692 | Weston, Florida, United States | — |
| Northwest Georgia Oncology Centers /ID# 284769 | Marietta, Georgia, United States | — |
| Rush University Medical Center /ID# 283095 | Chicago, Illinois, United States | — |
| Beth Israel Deaconess Medical Center /ID# 285204 | Boston, Massachusetts, United States | — |
| Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 282591 | Grand Rapids, Michigan, United States | — |
| The Mount Sinai Hospital /ID# 283535 | New York, New York, United States | — |
| Columbia University Medical Center /ID# 283510 | New York, New York, United States | — |
+ 54 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07728188